DEXA Bone Density: What "Normal" Really Means and Where Functional Optimal Begins

How a DEXA Scan Actually Measures Bone Density

Dual-energy X-ray absorptiometry (DXA) passes two low-dose X-ray beams through bone and soft tissue. The scanner calculates bone mineral density (BMD) in grams per square centimeter at specific skeletal sites, most commonly the lumbar spine (L1 through L4), femoral neck, and total hip. Results are then converted into two scores: the T-score, which compares your BMD to a healthy 30-year-old reference population, and the Z-score, which compares it to peers of your same age and sex [1].

The distinction matters. T-scores drive diagnostic classification and treatment decisions in postmenopausal women and men over 50. Z-scores are used for premenopausal women, men under 50, and children because age-matched comparison is more clinically meaningful in these groups [2]. A Z-score below -2.0 in a younger adult is labeled "below the expected range for age" and warrants investigation into secondary causes of bone loss, such as glucocorticoid use, celiac disease, or hyperparathyroidism.

Precision error also deserves attention. The International Society for Clinical Densitometry (ISCD) recommends that each DXA facility calculate its own least significant change (LSC), which is typically 0.03 to 0.05 g/cm² at the spine [2]. Changes smaller than this threshold between scans may reflect machine variability rather than true bone gain or loss.

The WHO "Normal" Cutoff and What It Was Designed to Do

The World Health Organization established T-score thresholds in 1994, originally as an epidemiologic tool for estimating fracture burden across populations, not as a clinical treatment trigger for individual patients [3]. The categories are straightforward. A T-score of -1.0 or above is normal. Between -1.0 and -2.5 is osteopenia. At -2.5 or below, you have osteoporosis.

These cutoffs were validated in postmenopausal white women. The WHO study group itself acknowledged that applying the same thresholds across all ethnic groups and both sexes required further data [3]. The ISCD and the American Association of Clinical Endocrinology (AACE) later endorsed these categories for postmenopausal women and men aged 50 and older, while recommending Z-scores for everyone else [4].

A key limitation: the -1.0 threshold was chosen because it roughly matched the lifetime fracture prevalence in the reference population. It was a statistical boundary, not a biological inflection point. Someone with a T-score of -0.9 and someone with a T-score of +0.5 both land in the "normal" bin, yet their 10-year fracture risks differ by a factor of roughly 1.5 to 2, depending on age and other FRAX inputs [5].

Functional Optimal: Where Preventive Clinicians Draw the Line

The concept of a "functional optimal" bone density range comes from preventive and functional medicine, not from any single guideline document. The premise is simple: rather than waiting for a patient to cross the -1.0 threshold into osteopenia, target a T-score zone associated with the lowest absolute fracture risk, typically between 0.0 and +1.0.

Dr. Felicia Cosman, former medical director of the National Osteoporosis Foundation, has stated: "A T-score of zero means your bone density matches the young-adult mean. Every standard deviation below that roughly doubles fracture risk at the hip" [6]. This dose-response relationship is continuous. There is no safe harbor at -0.9 simply because it clears a diagnostic label.

The 2020 AACE/ACE Clinical Practice Guidelines explicitly noted that fracture risk increases as BMD decreases even within the "normal" T-score range and recommended individualized risk assessment using FRAX for patients whose T-scores fall between -1.0 and -2.5 [4]. Some functional medicine practitioners extend this logic further, arguing that if a 45-year-old woman's T-score is -0.8 and declining on serial scans, the trajectory matters more than the snapshot.

The practical framework looks like this:

• T-score above +1.0: Bone density exceeds the young-adult mean. No intervention needed outside standard nutrition.
• T-score 0.0 to +1.0: Functional optimal. Low fracture risk. Maintain with weight-bearing exercise, adequate calcium (1,000 to 1 to 200 mg/day from food plus supplements if needed), and vitamin D (target 25-hydroxyvitamin D of 30 to 50 ng/mL) [7].
• T-score -1.0 to 0.0: Conventional "normal" but below the young-adult mean. This is the window where early lifestyle and hormonal interventions carry the best risk-to-benefit ratio.
• T-score -1.0 to -2.5: Osteopenia. FRAX assessment recommended. Pharmacotherapy considered if 10-year hip fracture risk exceeds 3% or major osteoporotic fracture risk exceeds 20% [5].
• T-score -2.5 or below: Osteoporosis. Pharmacotherapy indicated per every major guideline.

Why the Gap Between "Normal" and "Optimal" Matters Clinically

Fracture risk does not begin at a T-score of -2.5. The majority of fragility fractures actually occur in individuals classified as osteopenic, not osteoporotic, simply because the osteopenic population is much larger [8]. A prospective study published in JAMA found that among postmenopausal women who sustained hip fractures, 54% had T-scores above -2.5 at baseline [8].

The USPSTF recommends screening all women aged 65 and older, and younger postmenopausal women whose 10-year fracture risk (by FRAX) equals or exceeds that of a 65-year-old white woman without additional risk factors, roughly a 9.3% risk of major osteoporotic fracture [9]. But this screening recommendation focuses on detecting osteoporosis and high-risk osteopenia. It was not designed to identify patients in the -1.0 to 0.0 zone who could benefit from optimization strategies.

This is where the functional approach fills a gap. A premenopausal woman on an aromatase inhibitor, a man starting androgen deprivation therapy, or a patient taking long-term glucocorticoids may all have "normal" T-scores at baseline that are actively declining. Waiting for them to reach -1.0 before intervening means losing bone that is harder to rebuild than to maintain.

The AACE 2020 guideline acknowledged this by recommending baseline DXA for any patient initiating therapy known to cause bone loss, regardless of age or sex [4].

How to Raise Bone Density Toward Functional Optimal

Improving BMD requires a combination of mechanical loading, nutritional adequacy, hormonal optimization, and, in some cases, pharmacotherapy. The evidence supports a layered approach.

Resistance and impact training. A meta-analysis of 43 randomized controlled trials (N = 4,320) published in Bone found that combined resistance and weight-bearing exercise increased lumbar spine BMD by 0.013 g/cm² (95% CI: 0.008 to 0.018) over 6 to 24 months [10]. High-impact activities like jumping and plyometrics showed the largest effect sizes at the hip.

Calcium and vitamin D. The Endocrine Society Clinical Practice Guideline on vitamin D (2024) recommends maintaining serum 25(OH)D at or above 30 ng/mL for musculoskeletal health, with most adults requiring 1,000 to 2 to 000 IU of vitamin D3 daily to reach this threshold [7]. Calcium intake of 1,000 to 1 to 200 mg/day (dietary plus supplemental) remains the standard recommendation from the National Osteoporosis Foundation [6].

Hormone replacement therapy. The Women's Health Initiative (WHI) demonstrated that combined estrogen-progestin therapy reduced hip fracture risk by 34% (HR 0.66 to 95% CI 0.45 to 0.98) over 5.6 years of follow-up [11]. For women in early menopause with declining bone density, HRT initiated within 10 years of menopause onset carries a favorable risk-to-benefit profile for skeletal protection, according to the 2022 Menopause Society position statement [12].

Testosterone replacement in men. The Testosterone Trials (TTrials) showed that testosterone gel increased volumetric BMD of the lumbar spine by 7.5% over 12 months in men aged 65 and older with low testosterone [13]. The effect was most pronounced in the trabecular compartment, which is the first to respond to anabolic hormonal signals.

Pharmacotherapy for osteopenia with elevated risk. Bisphosphonates remain first-line for patients meeting FRAX treatment thresholds. In the FLEX trial extension, women who continued alendronate for 10 years maintained significantly higher femoral neck BMD than those switched to placebo at year 5 [14]. Denosumab (Prolia), a RANKL inhibitor, offers an alternative with 60 mg subcutaneous injection every 6 months, but carries rebound vertebral fracture risk upon discontinuation, a detail the FDA added to its label in 2022 [15].

When to Retest and How to Track Progress

The ISCD recommends follow-up DXA no sooner than 2 years after a baseline scan in most clinical scenarios, though 1-year intervals may be justified in patients on glucocorticoids or those initiating pharmacotherapy [2]. The same skeletal site and the same DXA machine should be used for serial monitoring to minimize precision error.

Dr. E. Michael Lewiecki, director of the New Mexico Clinical Research and Osteoporosis Center, has noted: "A change in BMD that exceeds the least significant change at your facility, typically around 3 to 5 percent at the spine, is the minimum needed to confirm a real biological effect rather than measurement noise" [2].

For patients in the functional-optimization zone (T-score -1.0 to 0.0), serial DXA every 2 to 3 years provides enough data points to detect a trend. If T-score is stable or improving, current interventions are working. A decline of more than 3% at the spine over 2 years in a premenopausal patient warrants investigation into secondary causes: thyroid function, celiac serology, 24-hour urinary calcium, and PTH [4].

Track ancillary biomarkers alongside DXA. Serum C-telopeptide (CTX) reflects bone resorption, while procollagen type 1 N-terminal propeptide (P1NP) reflects bone formation. These turnover markers change within 3 to 6 months of intervention, far earlier than BMD shifts appear on DXA, and can confirm whether a therapy is biochemically active before the next scan [16].

What Lowers Bone Density (and How to Identify Reversible Causes)

Bone density declines through a combination of aging, hormonal shifts, and modifiable exposures. The most common culprits:

Estrogen deficiency. The fastest bone loss occurs in the 5 to 7 years surrounding menopause. Women can lose 2 to 3% of BMD per year at the spine during this transition [12]. This is the single largest modifiable risk factor in the female population.

Glucocorticoids. Prednisone at doses of 5 mg/day or more for 3 months or longer causes measurable bone loss. The American College of Rheumatology recommends fracture risk assessment and potential bisphosphonate prophylaxis for any patient expected to remain on glucocorticoids for 3 or more months [17].

Proton pump inhibitors. Long-term PPI use (over 1 year) is associated with a modest increase in hip fracture risk (OR 1.26 to 95% CI 1.16 to 1.36), likely mediated through impaired calcium absorption [18]. The FDA issued a safety communication on this association in 2010 and updated it in 2011.

Hypogonadism in men. Low testosterone accelerates trabecular bone loss. Men with serum total testosterone consistently below 300 ng/dL should receive baseline DXA regardless of age, per the Endocrine Society guideline on testosterone therapy [19].

Vitamin D insufficiency. Serum 25(OH)D below 20 ng/mL impairs intestinal calcium absorption and triggers secondary hyperparathyroidism, which mobilizes calcium from bone. Correcting vitamin D to at least 30 ng/mL is the foundation of any bone-optimization protocol [7].

Excess alcohol. Consumption exceeding 3 units per day increases fracture risk independent of BMD, likely through direct toxic effects on osteoblasts and increased fall risk [5].

Putting It Together: A Functional Bone Density Protocol

For a patient with a T-score of -0.5, conventional medicine says "normal, recheck in a few years." A functional approach says: this patient is losing ground from peak bone mass, and the cost of intervening now (vitamin D optimization, resistance training, hormonal evaluation) is negligible compared to the cost of treating a fracture later.

The protocol is not complicated. Confirm vitamin D status, assess calcium intake, prescribe progressive resistance training 2 to 3 times weekly, evaluate hormonal contributors (estradiol in women, testosterone in men, TSH in both), and repeat DXA in 2 years to confirm the trajectory. If decline continues despite lifestyle optimization, the FRAX tool provides a quantitative basis for discussing pharmacotherapy before the T-score crosses -2.5 [5].

Bone is living tissue. It responds to load, hormones, and nutrients in predictable ways. Waiting for a diagnosis label is not the same thing as prevention. The difference between a T-score of -0.5 and a T-score of +0.5 is often just 12 to 24 months of deliberate, evidence-based action.